Communiqués AstraZeneca PLC

Actions

AZN

GB0009895292

Produits pharmaceutiques

Marché Fermé - London S.E. 17:35:24 08/09/2026			Varia. 5j.	Varia. 1 janv.
11 876,00 ^GBX	-1,38 %		-0,72 %	-13,88 %

18:50	Transcript : AstraZeneca PLC Presents at European Respiratory Society Congress, Sep-08-2026 05:00 PM
17:46	Principales actualités de la mi-journée : GE Aerospace va acquérir Consolidated Precision Products ; Qualcomm émet des bons de souscription d'actions au profit d'Amazon	MT

Communiqués

15:05	IMFINZI® (durvalumab) plus tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-stage small cell lung cancer	BU
13:51	Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials	BU
13:49	AstraZeneca : Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials	PU
05/09	ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer	BU
04/09	AstraZeneca : Etcamah in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer	PU
01/09	AstraZeneca completes global license agreement for oral EGFR inhibitor ZEGFROVY® (sunvozertinib) for lung cancer	BU
01/09	AstraZeneca : Enhertu plus pertuzumab approved in the EU as first new regimen in more than a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer	PU
01/09	AstraZeneca : completes global license agreement for oral EGFR inhibitor Zegfrovy for lung cancer	PU
27/08	TEZSPIRE demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints	BU
20/08	Foresite Labs Appoints Dr. Jorge Reis-Filho to Chief Strategy Officer and Operating Partner; Joins Foresite Capital as Venture Partner	AQ
18/08	AstraZeneca - Update on eVOLVE-Lung02 Phase III trial of volrustomig plus chemotherapy in metastatic non-small cell lung cancer	AQ
17/08	ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial	BU
17/08	TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO	BU
17/08	HUTCHMED Announces ORPATHYS plus TAGRISSO Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer	AQ
17/08	AstraZeneca : Enhertu demonstrated statistically significant and clinically meaningful improvement in progression-free survival as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial	PU
17/08	AstraZeneca : Update on eVOLVE-Lung02 Phase III trial of volrustomig plus chemotherapy in metastatic non-small cell lung cancer	PU
04/08	BITTER PILL TO SWALLOW?	AQ
27/07	Beyond De-risking: How European Companies Can Develop New Technologies In China	AQ
27/07	Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers	BU
27/07	AstraZeneca results: H1 and Q2 2026	BU
27/07	Astrazeneca: Q2 Earnings Snapshot	AQ
27/07	AstraZeneca : Update on Phase III trial of Ultomiris in adults and adolescents with thrombotic microangiopathy after haematopoietic stem cell transplant	PU
27/07	AstraZeneca : Update on Phase III trial of Ultomiris in adults and adolescents with thrombotic microangiopathy after haematopoietic stem cell transplant	PU
27/07	Half-year Financial Report	AQ
24/07	AstraZeneca : Enhertu plus pertuzumab recommended for approval in the EU by CHMP as 1st-line treatment for patients with HER2-positive metastatic breast cancer	PU